The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.

Nobuki FurubayashiAkinori MinatoTakahito NegishiNaotaka SakamotoYoohyun SongYoshifumi HoriToshihisa TomodaMirii HaradaShingo TamuraHiroki KobayashiYamato WadaKentaro KuroiwaNarihito SekiNaohiro FujimotoMotonobu Nakamura

Published in: OncoTargets and therapy (2022)

Pembrolizumab for advanced UC demonstrated similar changes in the eosinophil count, efficacy and toxicity in both older and younger patients. In patients with a poor PS, although toxicity was significantly lower, survival was significantly worse, and neither an increase in REC nor a decrease in NER were observed, but these values showed significant changes in patients with a good PS.

Keyphrases

end stage renal disease
newly diagnosed
oxidative stress
physical activity
ejection fraction
advanced non small cell lung cancer
community dwelling
middle aged
peritoneal dialysis